

# Primary Ciliary Dyskinesia in children

Dr Biju Thomas MD, FRCPCH  
Senior Consultant in Paediatric Respiratory Medicine  
KK Women's and Children's Hospital  
Singapore



KK Women's and  
Children's Hospital  
SingHealth

Image courtesy Nature 2007

SingHealth Academic Healthcare Cluster



Singapore  
General Hospital



KK Women's and  
Children's Hospital



National Cancer  
Centre Singapore



National Dental  
Centre Singapore



National Heart  
Centre Singapore



National  
Neuroscience Institute



Singapore National  
Eye Centre



Polyclinics  
SingHealth



Bright Vision  
Hospital

Sengkang  
Health

PATIENTS. AT THE HEART OF ALL WE DO.®

Partner in  
Academic Medicine

DUKE UNIVERSITY  
MEDICAL SCHOOL

# Structure of the talk

- Historical perspectives
- Cilia in humans
- Disorders of Motile Cilia – Primary Ciliary Dyskinesia
- Clinical features of PCD
- Diagnosis of PCD in the molecular age
- Management of PCD

# History

**1683: Anton de Hide – first description  
of ciliary movement**



# History

1834

- Purkinje and Valentin: discovered mammalian cilia


# History

1834

- Purkinje and Valentin: discovered mammalian cilia

1904

- Siewert
- Situs inversus and Bronchiectasis



# History

1834




- Purkinje and Valentin: discovered mammalian cilia

1904

- Siewert
- Situs inversus and Bronchiectasis

1933

- Kartagener
- Situs inversus, Bronchiectasis, Sinusitis



# History

1834

- Purkinje and Valentin: discovered mammalian cilia

1904

- Siewert
- Situs inversus and Bronchiectasis

1933

- Kartagener
- Situs inversus, Bronchiectasis, Sinusitis

1976

- Afzelius and Pederson
- Abnormal ciliary movement as the cause of the disorder

Afzelius BA. Science 1976; 193: 317-9

Pedersen & Mygind. Nature 1976; 262: 494-5




## A Human Syndrome Caused by Immotile Cilia

*Abstract. Four subjects who produced immotile sperm were studied. In three of the subjects, who had frequent bronchitis and sinusitis, there was no mucociliary transport, as measured by tracheobronchial clearance. Electron microscopy indicated that cilia from cells of these patients lack dynein arms.*

BJÖRN A. AFZELIUS

Wenner-Gren Institute,  
S-113 45 Stockholm, Sweden




*Nature Vol. 262 August 5 1976*

**nature**


**Absence of axonemal arms in nasal  
mucosa cilia in Kartagener's syndrome**

**HENNING PEDERSEN**

# Understanding cilia biology and genetics




Chlamydomonas Reinhardtii



Frog (Xenopus) larvae



Drosophila melanogaster







Zebra fish embryo


Image courtesy J Cell Biology 1996; Ninghui Shi

# Ciliated respiratory epithelium


- **Human respiratory cilia**
- ~ 200 cilia/cell
- 6 $\mu$ m long
- 0.3 $\mu$ m wide
- Frequency 10-14 Hz




# Cross section of human respiratory cilium




# Motile Cilia in Humans (9+2)




↑  
Motile 9+2




# Non-motile Cilia in Humans (9+0)




Kidney  
Renal cilia




Bile duct  
Cholangiocyte cilia



Pancreas  
Pancreatic duct cilia




Bone/cartilage  
Osteocyte/  
chondrocyte cilia




Eye  
Photoreceptor  
connecting cilia

Non-motile 9+0




# Motile Cilia in Humans (9+0)


Embryo  
Nodal cilia





← Motile 9+0



# Determination of Situs: Role of Nodal cilia




# Determination of Situs: Role of Nodal cilia



**Fluid current →  
molecular gradients &  
Activation of mechanosensors**

Nonaka Nature:2002

# Situs Inversus: Nodal Hypothesis





Nonaka Nature:2002

# Disorders of Cilia

**Disorders of  
Primary Cilia  
“Ciliopathies”**

**Disorders of  
Motile Cilia:  
PCD**

# Normal mucociliary clearance



← Mucus


← Periciliary fluid

← Epithelium

# Normal mucociliary clearance



# Normal mucociliary clearance



# Ciliary Dyskinesia

```
graph TD; A[Ciliary Dyskinesia] --> B[Primary]; A --> C[Secondary];
```

**Primary**

**Secondary**

# Primary Ciliary Dyskinesia: Epidemiology

- Prevalence: **1:15,000** (Caucasian)  
Higher in South Asians\* (1: 2200) – UK study  
Higher with parental consanguinity
- Autosomal recessive, Rarely X-linked or Dominant
- Significantly under diagnosed

*\*C O'Callaghan. Ped Pulmonology 2004*

# Clinical Presentation of PCD

- Infancy – late adulthood
- Manifestations vary with age
- Symptoms overlap with common respiratory diseases
- Late diagnosis is common, mean age at diagnosis: >4yr
- 30% have established bronchiectasis at diagnosis

Coren ME. Acta Paediatr 2002; 91: 667-669

Bush A. ERJ 1998; 12: 982-988, Noone PG. AJRCCM 2004; 169: 459-467

Hossain T. J Perinatology 2003; 23: 684-687

# Age-related prevalence of clinical features in PCD


PCD clinical feature	Youngest age when feature present in >50% of PCD	Youngest age when feature present in >80% of PCD
Neonatal respiratory distress	12hr of life	24hr of life
Organ laterality defects	Neonatal	
Recurrent otitis media with effusion	Infancy	Infancy
Year-round, daily wet cough	Infancy	Infancy
Year-round, daily nasal congestion	Infancy	Infancy
Recurrent LRTI	Infancy	Preschool
Chronic pansinusitis	Preschool	School age
Bronchiectasis	School age	Adult
Male infertility	-	Adults

Knowles MR, AJRCCM 2013

# Primary Ciliary Dyskinesia Rule


PICADAR		
Does the patient have a daily wet cough that started in early childhood?	<b>Yes</b> – complete PICADAR  <b>No</b> – <b>STOP</b> . PICADAR is not designed for patients without a wet cough	
1. Was the patient born pre-term or full term?	Term	2
2. Did the patient experience chest symptoms in the neonatal period (e.g. tachypnoea, cough, pneumonia)?	Yes	2
3. Was the patient admitted to a neonatal unit?	Yes	2
4. Does the patient have a situs abnormality (situs inversus or heterotaxy)?	Yes	4
5. Does the patient have a congenital heart defect?	Yes	2
6. Does the patient have persistent perennial rhinitis?	Yes	1
7. Does the patient experience chronic ear or hearing symptoms (e.g. glue ear, serous otitis media, hearing loss, ear perforation)?	Yes	1
<b>Total score =</b>		

PICADAR $\geq 5$		
	Southampton (UK)	Brompton (UK)
Sensitivity	90%	86%
Specificity	75%	73%



## PICADAR Probability Curve

Behan L et al. ERJ 2016



## Probability of PCD

PICADAR  
 $\geq 5$

>11%

PICADAR  
 $\geq 10$

>90%


Behan L et al. ERJ 2016

# Diagnosis of PCD in the molecular age

# MAKING A DIAGNOSIS


Rare

No Gold Standard Test



Single Symptoms - nonspecific

Tests  
-Expensive  
- Equipment  
-Expertise



Pediatric Pulmonology 51:115–132 (2016)

— State of the Art —

## Diagnosis, Monitoring, and Treatment of Primary Ciliary Dyskinesia: PCD Foundation Consensus Recommendations Based on State of the Art Review

Adam J. Shapiro, MD,<sup>1\*</sup> Maimoona A. Zariwala, PhD,<sup>2</sup> Thomas Ferkol, MD,<sup>3</sup> Stephanie D. Davis, MD,<sup>4</sup>  
Scott D. Sagel, MD, PhD,<sup>5</sup> Sharon D. Dell, MD,<sup>6</sup> Margaret Rosenfeld, MD,<sup>7</sup> Kenneth N. Olivier, MD,<sup>8§</sup>  
Carlos Milla, MD,<sup>9</sup> Sam J. Daniel, MD,<sup>10</sup> Adam J. Kimple, MD,<sup>11</sup> Michele Manion,<sup>12</sup>  
Michael R. Knowles, MD,<sup>13</sup> and Margaret W. Leigh, MD,<sup>14</sup>  
for the Genetic Disorders of Mucociliary Clearance Consortium

# European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia



Jane S. Lucas<sup>1,2</sup>, Angelo Barbato<sup>3</sup>, Samuel A. Collins <sup>1,2</sup>, Myrofora Goutaki<sup>4,5</sup>, Laura Behan<sup>1,2</sup>, Daan Caudri<sup>6,7</sup>, Sharon Dell<sup>8,9</sup>, Ernst Eber<sup>10</sup>, Estelle Escudier<sup>11,12</sup>, Robert A. Hirst<sup>13</sup>, Claire Hogg<sup>14</sup>, Mark Jorissen<sup>15</sup>, Philipp Latzin<sup>5</sup>, Marie Legendre<sup>11,12</sup>, Margaret W. Leigh<sup>16</sup>, Fabio Midulla<sup>17</sup>, Kim G. Nielsen<sup>18</sup>, Heymut Omran<sup>19</sup>, Jean-Francois Papon<sup>20,21</sup>, Petr Pohunek<sup>22</sup>, Beatrice Redfern<sup>23</sup>, David Rigau<sup>24</sup>, Bernhard Rindlisbacher<sup>25</sup>, Francesca Santamaria<sup>26</sup>, Amelia Shoemark<sup>14</sup>, Deborah Snijders<sup>3</sup>, Thomy Tonia<sup>4</sup>, Andrea Titieni<sup>19</sup>, Woolf T. Walker<sup>1,2</sup>, Claudius Werner<sup>19</sup>, Andrew Bush<sup>14</sup> and Claudia E. Kuehni<sup>4</sup>

**Cite this article as:** Lucas JS, Barbato A, Collins SA, *et al.* European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. *Eur Respir J* 2017; 49: 1601090 [https://doi.org/10.1183/13993003.01090-2016].

# AMERICAN THORACIC SOCIETY DOCUMENTS

## Diagnosis of Primary Ciliary Dyskinesia

### An Official American Thoracic Society Clinical Practice Guideline: Executive Summary


Adam J. Shapiro, Stephanie D. Davis, Deepika Polineni, Michele Manion, Margaret Rosenfeld, Sharon D. Dell, Mark A. Chilvers, Thomas W. Ferkol, Maimoona A. Zariwala, Scott D. Sagel, Maureen Josephson, Lucy Morgan, Ozge Yilmaz, Kenneth N. Olivier, Carlos Milla, Jessica E. Pittman, M. Leigh Anne Daniels, Marcus Herbert Jones, Ibrahim A. Janahi, Stephanie M. Ware, Sam J. Daniel, Matthew L. Cooper, Lawrence M. Nogee, Billy Anton, Tori Eastvold, Lynn Ehrne, Elena Guadagno, Michael R. Knowles, Margaret W. Leigh, and Valery Lavergne; on behalf of the American Thoracic Society Assembly on Pediatrics

THIS OFFICIAL CLINICAL PRACTICE GUIDELINE OF THE AMERICAN THORACIC SOCIETY WAS APPROVED MAY 2018



Am J Respir Crit Care Med Vol 197, Iss 12, pp 1524–1533, Jun 15, 2018

# No Gold Standard Diagnostic test



NO = Nitric Oxide

HVMA = High speed Video Microscopy Analysis


TEM = Transmission Electron Microscopy

IF = Immunofluorescence


# Nasal NO

nNO	Study Population	Sampling method	Threshold nl/min	Sensitivity	Specificity
Marthin 2011	117 referrals 14 PCD	Breath holding with oral exhalation	72	1.0	0.94
Leigh 2013	155 referrals 71 PCD	Oral exhalation, velum closure	77	0.99	0.75
Beydon 2015	86 referrals 49 PCD	Velum closure	82	0.91	0.86
Jackson 2015	301 referrals 34 PCD	Breath Hold, velum closure	30	0.90	0.95

# Nasal NO in PCD and healthy controls



# NIOX MINO<sup>®</sup> Nasal




**Chemiluminescence analyser**



**Electrochemical analyser**

# NIOX MINO<sup>®</sup> Nasal



**Chemiluminescence analyser**



**Electrochemical analyser**

# Obtaining sample: Nasal brushing For HVMA, TEM and IF



# New diagnostic service for Primary Ciliary Dyskinesia at KKH

*Dr Biju Thomas*



*Consultant, Respiratory Medicine Service, Department of Paediatrics, KK Women's and Children's Hospital*




# Ciliary beat pattern is associated with specific ultrastructural defects in primary ciliary dyskinesia

*JACI 2003*

Mark A. Chilvers, MRCPCH, Andrew Rutman, and Christopher O'Callaghan, FRCPCH, PhD *Leicester, United Kingdom*




# Immotile cilia



# Stiff beating cilia




# Circular beating cilia




r 21/09/2009 000000 30 fps



# Transmission Electron Microscopy



# Immunofluorescence



DNAH5  
DNAI2  
DNALI1  
RSPH4A  
RSPH1  
RSPH 9

# Genetics



# Genetics

- Genetically heterogeneous, **NOT** a single gene/locus
- Majority autosomal recessive
- Rarely, dominant or X-linked
- ~39 disease causing mutations identified
- Bi allelic mutations in **one** disease causing **gene**
- No documented cases of digenic inheritance  
(heterozygous mutations in two different PCD gene)

Genetic basis of about 30% patients with PCD - unknown

PCD genes	Prevalence in PCD	Ciliary structural defect	Detected on current commercial PCD NGS panels
NME8	+	Partial ODA defect	Yes
DNAH5	++++	ODA defect	Yes
DNAI1	+++	ODA defect	Yes
DNAI2	++	ODA defect	Yes
DNAL1	+	ODA defect	Yes
CCDC114	++	ODA defect	Yes
CCDC103	++	ODA ± defect	Yes
DNAAF1	++	ODA and IDA defect	Yes
DNAAF2	++	ODA and IDA defect	Yes
DNAAF3	+	ODA and IDA defect	Yes
LRRC6	++	ODA and IDA defect	Yes
HEATR2	+	ODA and IDA defect	Yes
RPGR	+	Normal	Yes
OFD1	+	Normal	Yes
DNAH11	+++	Normal	Yes
CCDC39	+++	IDA defect + MTD defect	Yes
CCDC40	+++	IDA defect + MTD defect	Yes
RSPH9	+	Central pair defect or normal	Yes
RSPH4A	++	Central pair defect or normal	Yes
RSPH1	++	Central pair defect or normal	
RSPH3	+	Central pair defect or normal	
CCNO	+	Oligocilia (residual axoneme normal)	
MCIDAS	+	Oligocilia (residual axoneme abnormal)	
DNAH8	+	Not available	
CCDC151	++	ODA defect	
ARMC4	++	ODA defect	
DYX1C1	+	ODA and IDA defect	
C21orf59	+	ODA and IDA defect	
ZMYND10	++	ODA and IDA defect	
SPAG1	++	ODA and IDA defect	
HYDIN	+	Normal	
CCDC164 (DRC1)	+	Mostly normal (N-DRC defect)	
CCDC65 (DRC2)	+	Mostly normal (N-DRC defect)	

**% of all PCDs**

+ : <1%  
 ++ : 1-4%  
 +++ : 4-10%  
 ++++ : >15%

PCD genes	Prevalence in PCD	Ciliary structural defect	Detected on current commercial PCD NGS panels
NME8	+	Partial ODA defect	Yes
DNAH5	++++	ODA defect	Yes
DNAI1	+++	ODA defect	Yes
DNAI2	++	ODA defect	Yes
DNAL1	+	ODA defect	Yes
CCDC114	++	ODA defect	Yes
CCDC103	++	ODA ± defect	Yes
DNAAF1	++	ODA and IDA defect	Yes
DNAAF2	++	ODA and IDA defect	Yes
DNAAF3	+	ODA and IDA defect	Yes
LRRC6	++	ODA and IDA defect	Yes
HEATR2	+	ODA and IDA defect	Yes
RPGR	+	Normal	Yes
OFD1	+	Normal	Yes
DNAH11	+++	Normal	Yes
CCDC39	+++	IDA defect + MTD defect	Yes
CCDC40	+++	IDA defect + MTD defect	Yes
RSPH9	+	Central pair defect or normal	Yes
RSPH4A	++	Central pair defect or normal	Yes
RSPH1	++	Central pair defect or normal	
RSPH3	+	Central pair defect or normal	
CCNO	+	Oligocilia (residual axoneme normal)	
MCIDAS	+	Oligocilia (residual axoneme abnormal)	
DNAH8	+	Not available	
CCDC151	++	ODA defect	
ARMC4	++	ODA defect	
DYX1C1	+	ODA and IDA defect	
C21orf59	+	ODA and IDA defect	
ZMYND10	++	ODA and IDA defect	
SPAG1	++	ODA and IDA defect	
HYDIN	+	Normal	
CCDC164 (DRC1)	+	Mostly normal (N-DRC defect)	
CCDC65 (DRC2)	+	Mostly normal (N-DRC defect)	

**% of all PCDs**

+	: <1%
++	: 1-4%
+++	: 4-10%
++++	: >15%

PCD genes	Prevalence in PCD	Ciliary structural defect	Detected on current commercial PCD NGS panels
NME8	+	Partial ODA defect	Yes
DNAH5	++++	ODA defect	Yes
DNAI1	+++	ODA defect	Yes
DNAI2	++	ODA defect	Yes
DNAL1	+	ODA defect	Yes
CCDC114	++	ODA defect	Yes
CCDC103	++	ODA ± defect	Yes
DNAAF1	++	ODA and IDA defect	Yes
DNAAF2	++	ODA and IDA defect	Yes
DNAAF3	+	ODA and IDA defect	Yes
LRRC6	++	ODA and IDA defect	Yes
HEATR2	+	ODA and IDA defect	Yes
RPGR	+	Normal	Yes
OFD1	+	Normal	Yes
DNAH11	+++	Normal	Yes
CCDC39	+++	IDA defect + MTD defect	Yes
CCDC40	+++	IDA defect + MTD defect	Yes
RSPH9	+	Central pair defect or normal	Yes
RSPH4A	++	Central pair defect or normal	Yes
RSPH1	++	Central pair defect or normal	
RSPH3	+	Central pair defect or normal	
CCNO	+	Oligocilia (residual axoneme normal)	
MCIDAS	+	Oligocilia (residual axoneme abnormal)	
DNAH8	+	Not available	
CCDC151	++	ODA defect	
ARMC4	++	ODA defect	
DYX1C1	+	ODA and IDA defect	
C21orf59	+	ODA and IDA defect	
ZMYND10	++	ODA and IDA defect	
SPAG1	++	ODA and IDA defect	
HYDIN	+	Normal	
CCDC164 (DRC1)	+	Mostly normal (N-DRC defect)	
CCDC65 (DRC2)	+	Mostly normal (N-DRC defect)	

**% of all PCDs**

+ : <1%  
 ++ : 1-4%  
 +++ : 4-10%  
 ++++ : >15%

Shapiro AJ. Ped Pul 2016

# Primary Ciliary Dyskinesia (PCD)/Immotile Cilia Syndrome and Cystic Fibrosis Sequencing Panel

Print Test Description  
Forms

Summary and Pricing Clinical Features and Genetics Citations Methods Ordering/Specimens

### TEST METHODS

- [NextGen Sequencing](#)
- [Deletion/Duplication Testing Via Array Comparative Genomic Hybridization](#)

Order Kits

### Sequencing

Test Code	Test	Total Price	CPT Codes	<a href="#">Copy CPT Codes</a>
1059	Genes x (32)	\$2090.00	81223, 81479(x31)	<a href="#">Add to Order</a>

### Pricing Comment

Our most cost-effective testing approach is NextGen sequencing with Sanger sequencing supplemented as needed to ensure sufficient coverage and to confirm NextGen calls that are pathogenic, likely pathogenic or of uncertain significance. If, however, full gene Sanger sequencing only is desired (for purposes of insurance billing or STAT turnaround time for example), please see link below for Test Code, pricing, and turnaround time information. If you would like to order a subset of these genes [contact us](#) to discuss pricing.

[For Sanger Sequencing click here.](#)

### Targeted Testing

For ordering targeted known variants, please proceed to our [Targeted Variants](#) landing page.

### Turnaround Time

The great majority of tests are completed within 28 days.

## PCD: Recommended Panel of Diagnostic Tests

	Potential for <b>false positive</b>	Potential for <b>false negative</b>
Nasal NO (nNO) (<77nl/min)	Low*	Low
Transmission Electron Microscopy (TEM)	Variable†	Variable‡
High speed Video Microscopy Analysis (HVMA)	Variable§	Moderate§
PCD genetic test	Low¶	Moderate¶
Immunofluorescence (IF)	Unknown	Unknown

\* CF needs to be excluded. False positive: Viral infection, Epistaxis, Non atopic sinusitis.

† Infection, irritants, improper specimen handling/processing, inexperience.

‡ Several disease causing mutations can have normal TEM or only subtle changes.

§ Secondary changes, subtle changes may be missed (inexperience).

¶ 30% PCD have no identifiable mutation, may miss large insertions/deletions.

# AMERICAN THORACIC SOCIETY DOCUMENTS

## Diagnosis of Primary Ciliary Dyskinesia


### An Official American Thoracic Society Clinical Practice Guideline: Executive Summary


Adam J. Shapiro, Stephanie D. Davis, Deepika Polineni, Michele Manion, Margaret Rosenfeld, Sharon D. Dell, Mark A. Chilvers, Thomas W. Ferkol, Maimoona A. Zariwala, Scott D. Sagel, Maureen Josephson, Lucy Morgan, Ozge Yilmaz, Kenneth N. Olivier, Carlos Milla, Jessica E. Pittman, M. Leigh Anne Daniels, Marcus Herbert Jones, Ibrahim A. Janahi, Stephanie M. Ware, Sam J. Daniel, Matthew L. Cooper, Lawrence M. Nogee, Billy Anton, Tori Eastvold, Lynn Ehrne, Elena Guadagno, Michael R. Knowles, Margaret W. Leigh, and Valery Lavergne; on behalf of the American Thoracic Society Assembly on Pediatrics


THIS OFFICIAL CLINICAL PRACTICE GUIDELINE OF THE AMERICAN THORACIC SOCIETY WAS APPROVED MAY 2018





Am J Respir Crit Care Med Vol 197, Iss 12, pp 1524–1533, Jun 15, 2018














	Clinical +	≥ 1 Diagnostic Test
Newborn (0-1m)	Situs inversus totalis + Unexplained neonatal respiratory distress at term birth	TEM Genetic test HVMA
Children (1m-5 years)	≥2 major PCD clinical criteria	TEM Genetic test HVMA
Children >5 years & Adults	≥2 major PCD clinical criteria	<b>Nasal NO</b> TEM Genetic test HVMA

TEM	: Diagnostic abnormality
Genetic test	: Biallelic mutation in one PCD associated gene
HVMA	: Persistent and diagnostic abnormality on ≥2 occasions
Nasal NO	: <77nl/min on 2 occasions, >2m apart, with CF excluded

#### Major clinical criteria\*

1. Unexplained neonatal respiratory distress (term) with lobar collapse ± CPAP/O<sub>2</sub> for >24 hr.
2. Any organ laterality defect – SIT, SA or Heterotaxy
3. Daily, year-round wet cough starting in the first year of life **OR** Bronchiectasis on chest CT
4. Daily, year-round nasal congestion starting in the first year of life **OR** pansinusitis on sinus CT

\*Exclude other differentials such as CF and immune deficiencies.

Shapiro AJ. Ped Pul 2016

# Choosing the test(s)

- Diagnostic test accuracy
- Confidence in the estimates of the test
- Patient values and preferences
- Costs
- Feasibility
- Acceptability

# Management of patients with PCD

**No Cure**

Principles of management

Respiratory

ENT


Fertility  
issues

Genetic  
counseling

## Summary of **recommended** respiratory management of children with PCD

Clinic visit	2-4 times/year
Sputum/cough swab	At every clinic visit If respiratory exacerbations
Culture for Non Tuberculous Mycobacteria/Fungi	Every 2 years If not responding to culture-directed antibiotics Consider screening for ABPA
Spirometry	2-4 times/year
Imaging: CXR	At diagnosis, once every 2-4 years During severe exacerbations
Imaging: Chest CT	At least once (age ~ 5-7 years)
<b>Chest Physiotherapy, exercise</b>	Daily
Vaccinations	Routine childhood vaccines Pneumococcal vaccination Annual influenza vaccine RSV immunoprophylaxis in the first winter (case by case basis)
<b>Antibiotics for exacerbations</b>	Mild – Oral Severe - IV

# Physiotherapy



## Respiratory therapies to **consider on a case by case basis** in PCD

Long term antibiotics	Oral	Co-trimoxazole Macrolide
	Nebulised	Chronic PA colonisation
Inhaled hyperosmolar agents	Hypertonic saline (3-7%)	Limited benefits in non-CF bronchiectasis No studies in PCD Proper equipment sterilization – important
	Mannitol	Limited benefits in non-CF bronchiectasis No studies in PCD
DNAse (dornase-alfa)		No trials in PCD, few case reports Adverse effects in non-CF bronchiectasis
Inhaled bronchodilators		Before nebulised hypertonic saline Reactive airway disease
ICS+LABA		Consider if associated asthma
IVIg		Consider if humoral immune deficiency present
Lobectomy		Severe localised bronchiectasis, caution
Lung transplantation		Caution - situs anomalies

# Management of ENT problems

- Chronic otitis media with effusion - universal
  - grommets: controversial
  - antibiotics
  - hearing tests, hearing aids, speech therapy
  - tympanoplasty
- Chronic rhinosinusitis
  - saline lavages
  - nasal steroids
  - antibiotics
  - surgery

Involve  
Paediatric ENT Surgeon &  
Speech Therapist



Forum | Clinical Trials | Volunteer | Search Site



**DONATE**  
There are many ways to donate, find the one that's right for you!

**VOLUNTEER**  
Support your local PCD community with a volunteer opportunity that's right for you.

**ADVOCATE**  
Join the fight for PCD! Help raise awareness and support efforts to find a cure.

**LATEST NEWS & EVENTS**

- ATS Webinar on PCD 10/20/2016
- PCDF CARE Day: Boston Children's Nov. 6, 2016
- PCD On The Move 2016: Advances in Primary Ciliary Dyskinesia Research, Diagnosis & Care
- Call for Scientific Abstracts and Case Reports 2016
- PCDF Clinical Centers Network

**UNMASK THE FACES OF PCD**

**25,000+ people**  
in the United States have PCD and less than 400 know it. Unmask the faces of PCD.  
[READ MORE...](#)

**STAY INFORMED**

Want to be in the loop on the latest PCD news?  
[SIGN UP NOW!](#)



This site uses cookies to enhance your visit, and by continuing to use the site you agree to their use. You can change this and find out more here



Search the site



What is PCD? Find out what PCD is, its cause and how it can be treated, plus much more.

Need to talk? Visit our Online Community to chat to people who have experience of PCD in their lives.

Latest News

- ERS Patient Event 2016 Wednesday, October 05, 2016
Have you had your flu jab? Wednesday, October 05, 2016
25th Anniversary Cruise Party 4th September 2016 Thursday, September 08, 2016
PCD Day Video 2016 Thursday, July 28, 2016
Lastest research news from the Royal Brompton Thursday, July 21, 2016
PCD Day at Woburn Safari Park Thursday, June 23, 2016

Tweets by @PCD\_UK



PCD Family Support UK 18 October at 08:35

Welcome

Welcome to our website which was created in 2010 with the help of a grant from Jeans for Genes.

The website provides an up to date information service about the condition, how it is diagnosed and how to live with it on a daily basis. Please look at the video case studies with real life people affected by PCD telling their stories.

Primary Ciliary Dyskinesia (PCD) is an inherited, relatively rare condition associated with the abnormality of cilia (microscopic hairs that beat in the airways, sweeping secretions out of the respiratory tract). PCD may affect the lungs, nose, sinuses, ears and fertility.

The condition involves recurrent infections in the nose, ears, sinuses and lungs. If left untreated can lead to a form of lung damage known as 'bronchiectasis'.

Up to 50% of patients with PCD also have dextrocardia (heart on the right side) and situs inversus (internal organs on opposite side to normal).

The mainstay of treatment is chest physiotherapy and targeted antibiotics enabling individuals to lead normal lives. Any problems resulting from PCD vary from person to person.

We hope you find the site useful and welcome any comments or suggestions about it.

Wish to donate? All donations are gratefully received, alternatively find out how you can fundraise.

Contact us Please contact us if you need any further information from our adult or children's contact.



# Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia

<http://bestcilia.eu/>



# Conclusions

- PCD is a rare disease
- Symptoms overlap with common respiratory diseases
- Awareness and high index of suspicion are crucial
- There is no single gold standard diagnostic test
- Know when to refer to a specialised PCD centre
- Early diagnosis and management may improve outcome



***Thank you***

[biju.thomas@singhealth.com.sg](mailto:biju.thomas@singhealth.com.sg)